Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on MRNS. Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

MRNS stock opened at $0.31 on Monday. The firm has a 50-day moving average price of $1.15 and a 200-day moving average price of $1.29. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26. The stock has a market capitalization of $17.10 million, a P/E ratio of -0.13 and a beta of 1.26.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at $34,000. AQR Capital Management LLC boosted its position in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth about $64,000. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.